APVO - Aptevo Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-2.672M

Cash

10.25M

Avg Qtr Burn

-5.737M

Short % of Float

16.39%

Insider Ownership

0.06%

Institutional Own.

0.30%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APVO436 (anti-CD123 x anti-CD3) +/- Venetoclax + Azacitidine Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG.APV-527 (4-1BB x 5T4) Details Cancer, Solid tumor/s, Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer, Colorectal cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.